Mangalam Drugs And Organics Ltd vs Morepen Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Mangalam Drugs and Organics Ltd is ₹ 30.05 as of 05 May 15:30 . The P/E Ratio of Mangalam Drugs and Organics Ltd changed from 17.5 on March 2025 to 17.5 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 years The Market Cap of Mangalam Drugs and Organics Ltd changed from ₹ 146.65 crore on March 2024 to ₹ 117.48 crore on March 2025 . This represents a CAGR of -10.50% over 2 yearsThe Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 years The revenue of Mangalam Drugs and Organics Ltd for the Dec '25 is ₹ 58.6 crore as compare to the Sep '25 revenue of ₹ 49.57 crore. This represent the growth of 18.22% The revenue of Morepen Laboratories Ltd for the Dec '25 is ₹ 487.97 crore as compare to the Sep '25 revenue of ₹ 442.04 crore. This represent the growth of 10.39% The ebitda of Mangalam Drugs and Organics Ltd for the Dec '25 is ₹ -1.32 crore as compare to the Sep '25 ebitda of ₹ -2.81 crore. This represent the decline of -53.02% The ebitda of Morepen Laboratories Ltd for the Dec '25 is ₹ 50.12 crore as compare to the Sep '25 ebitda of ₹ 61.16 crore. This represent the decline of -18.05% The net profit of Mangalam Drugs and Organics Ltd changed from ₹ 2.68 crore to ₹ -9.84 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 27.5 crore over 7 quarters. This represents a CAGR of -14.50% The Dividend Payout of Mangalam Drugs and Organics Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Ltd was formerly incorporated on April 18, 1972 as a private limited company with the name Advent Pharma Pvt Ltd. On July 1, 1997, the Company changed their name from Advent Pharma Pvt Ltd to Mangalam Drugs and Organics Pvt Ltd. Thereafter, the Company converted into a Public Limited Company and name of the Company was changed from Advent Pharma Ltd to Mangalam Drugs and Organics Ltd on August 10, 2001.
The company was promoted by Dhoot family.
The company was established with a view to set up a plant for manufacture of organic and inorganic chemicals. The company is engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates.
The company has their manufacturing facilities at Vapi in Gujarat and Sangamner in Maharashtra.

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

FAQs for the comparison of Mangalam Drugs and Organics Ltd and Morepen Laboratories Ltd

Which company has a larger market capitalization, Mangalam Drugs and Organics Ltd or Morepen Laboratories Ltd?

Market cap of Mangalam Drugs and Organics Ltd is 48 Cr while Market cap of Morepen Laboratories Ltd is 2,298 Cr

What are the key factors driving the stock performance of Mangalam Drugs and Organics Ltd and Morepen Laboratories Ltd?

The stock performance of Mangalam Drugs and Organics Ltd and Morepen Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mangalam Drugs and Organics Ltd and Morepen Laboratories Ltd?

As of May 5, 2026, the Mangalam Drugs and Organics Ltd stock price is INR ₹30.66. On the other hand, Morepen Laboratories Ltd stock price is INR ₹41.94.

How do dividend payouts of Mangalam Drugs and Organics Ltd and Morepen Laboratories Ltd compare?

To compare the dividend payouts of Mangalam Drugs and Organics Ltd and Morepen Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.